. Author manuscript; available in PMC: 2022 Feb 18.

Published in final edited form as: Obesity (Silver Spring). 2020 Sep;28(9):1678–1686. doi: 10.1002/oby.22936

Table 2.

Cancer incidence by study arm in 4,859 Look AHEAD participants

	DSE		ILI
	Number of Events	Rate^*	Number of Events	Rate^*	HR (95% Cl)	P-value
Cancer Type	Number of Events	Rate^*	Number of Events	Rate^*	HR (95% Cl)	P-value
All Cancers	352	14.2	332	13.2	0.93(0.80, 1.08)	0.32
Obesity Related^¶	185	7.3	158	6.1	0.84(0.68, 1.04)	0.10
Non-Obesity Related	167	6.6	174	6.7	1.02(0.83,1.27)	0.83
Men
All Cancers	177	18.2	165	16.6	0.91 (0.74, 1.12)	0.38
Obesity Related^¶	49	4.8	39	3.7	0.78(0.51,1.19)	0.25
Non-Obesity Related	128	13.0	126	12.5	0.96(0.75, 1.22)	0.73
Women
All Cancers	175	11.6	167	11.0	0.94(0.76, 1.16)	0.58
Obesity Related^¶	136	9.0	119	7.7	0.86(0.67, 1.10)	0.23
Non-Obesity Related	39	2.5	48	3.0	1.22(0.80,1.86)	0.36

DSE: Diabetes Support and Education. ILI: Intensive Lifestyle Intervention. HR: hazard ratio

Rate per 1,000 person-years

^¶

Included esophagus, colon, rectum, kidney, pancreas, stomach, liver, gallbladder, thyroid, and multiple myeloma in men and women, and additional uterus, ovary, post-menopausal breast in women.